OnKure Therapeutics Inc Dossier
Qualitative Analysis
Business overview
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines targeting biologically validated drivers of cancers and other diseases underserved by available therapies. The company leverages a structure-based and computational chemistry-driven drug design platform to build a pipeline of tumor-agnostic small-molecule candidates designed to optimize efficacy and tolerability. OnKure's lead clinical program is OKI-219, a highly selective, orally bioavailable inhibitor of phosphoinositide 3-kinase alpha (PI3K̑) harboring the H1047R mutation. OKI-219 is designed to preserve wild-type PI3K̑, thereby avoiding class-limiting toxicities such as hyperglycemia, stomatitis, or rash. The company is evaluating OKI-219 in the Phase 1a/1b PIKture-01 trial as a monotherapy and in combination with standard-of-care agents for advanced solid tumors and metastatic breast cancer. Additionally, OnKure is advancing next-generation PI3K̑ pan-mutant inhibitors (targeting H1047R, E545K, and E542K mutations) and has initiated discovery programs in vascular malformations.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the development of next-generation PI3Kα pan-mutant selective inhibitors, specifically OKI-345 for breast cancer and OKI-355 for vascular anomalies, designed to selectively target mutant PI3Kα while sparing wild-type PI3Kα.
Expected impact: Aims to deliver best-in-class precision oncology and systemic chronic therapies with a wider therapeutic index and minimal drug-drug interactions.
Deciding not to independently pursue further clinical development of the Phase 1 candidate OKI-219 beyond completing the ongoing PIKture-01 trial triplets, shifting corporate resources to the next-generation pan-mutant programs.
Expected impact: Optimizes capital allocation and focuses development efforts on candidates with broader pan-mutant coverage.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
All-stock reverse merger to transition OnKure into a publicly traded entity (NASDAQ: OKUR), securing a public listing and combining cash resources to fund the precision oncology pipeline.
Financial impact: Combined cash resources of approximately $120 million at close (including a concurrent $65 million PIPE financing), extending the initial cash runway into Q4 2026.